<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Resist Infect Control</journal-id><journal-id journal-id-type="iso-abbrev">Antimicrob Resist Infect Control</journal-id><journal-title-group><journal-title>Antimicrobial Resistance and Infection Control</journal-title></journal-title-group><issn pub-type="epub">2047-2994</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7449072</article-id><article-id pub-id-type="publisher-id">799</article-id><article-id pub-id-type="doi">10.1186/s13756-020-00799-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1501-2763</contrib-id><name><surname>Fokam</surname><given-names>Joseph</given-names></name><address><email>fokamjoseph@circb.cm</email><email>josephfokam@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Takou</surname><given-names>Desire</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Semengue</surname><given-names>Ezechiel Ngoufack Jagni</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Teto</surname><given-names>Georges</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Beloumou</surname><given-names>Grace</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dambaya</surname><given-names>Beatrice</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Santoro</surname><given-names>Maria-Mercedes</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Mossiang</surname><given-names>Leonella</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Billong</surname><given-names>Serge Clotaire</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Cham</surname><given-names>Fatim</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Sosso</surname><given-names>Samuel Martin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Temgoua</surname><given-names>Edith Saounde</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Nanfack</surname><given-names>Aubin Joseph</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Moudourou</surname><given-names>Sylvie</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kamgaing</surname><given-names>Nelly</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kamgaing</surname><given-names>Rachel</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ngako Pamen</surname><given-names>Joelle Nounouce</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Etame</surname><given-names>Mireille Mpoudi Ngole</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Bissek</surname><given-names>Anne-Cecile Z.-K.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Elat</surname><given-names>Jean-Bosco N.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Moussi</surname><given-names>Emmanuel Eben</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Colizzi</surname><given-names>Vittorio</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Perno</surname><given-names>Carlo-Federico</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Ndjolo</surname><given-names>Alexis</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><collab>On behalf of the VIROFORUM</collab></contrib><aff id="Aff1"><label>1</label>Chantal BIYA International Reference Centre for research on HIV/AIDS prevention and management, Yaound&#x000e9;, Cameroon </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.29273.3d</institution-id><institution-id institution-id-type="ISNI">0000 0001 2288 3199</institution-id><institution>Faculty of Health Sciences, </institution><institution>University of Buea, </institution></institution-wrap>Buea, Cameroon </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.415857.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 0668 6654</institution-id><institution>National HIV Drug Resistance Working Group, Ministry of Public Health, </institution></institution-wrap>Yaound&#x000e9;, Cameroon </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.412661.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2173 8504</institution-id><institution>Faculty of Medicine and Biomedical Sciences, </institution><institution>University of Yaound&#x000e9; I, </institution></institution-wrap>Yaound&#x000e9;, Cameroon </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.6530.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2300 0941</institution-id><institution>University of Rome Tor Vergata, </institution></institution-wrap>Rome, Italy </aff><aff id="Aff6"><label>6</label>Evangelic University of Cameroon, Bandjoun, Cameroon </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.460723.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0647 4688</institution-id><institution>HIV Treatment Centre, </institution><institution>Yaound&#x000e9; Central Hospital, </institution></institution-wrap>Yaound&#x000e9;, Cameroon </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.452676.4</institution-id><institution>Central Technical Group, National AIDS Control Committee, </institution></institution-wrap>Yaound&#x000e9;, Cameroon </aff><aff id="Aff9"><label>9</label>World Health Organisation, Regional Office for Africa (AFRO), Brazzaville, Congo </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.415857.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 0668 6654</institution-id><institution>Department of Disease, Epidemics and Pandemics Control, Ministry of Public Health, </institution></institution-wrap>Yaound&#x000e9;, Cameroon </aff><aff id="Aff11"><label>11</label>HIV Treatment Centre, Military Hospital, Yaound&#x000e9;, Cameroon </aff><aff id="Aff12"><label>12</label>Division of Health Operational Research, Yaound&#x000e9;, Cameroon </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="GRID">grid.4708.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 2822</institution-id><institution>University of Milan, </institution></institution-wrap>Milan, Italy </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>8</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>8</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>143</elocation-id><history><date date-type="received"><day>25</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>6</day><month>8</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Sub-Saharan African countries are transitioning to dolutegravir-based regimens, even for patients with extensive previous drug exposure, including first-generation integrase strand-transfer inhibitors (INSTI) such as raltegravir. Such exposure might have implications on cross-resistance to dolutegravir-based antiretroviral therapies (ART).</p></sec><sec><title>Case presentation</title><p id="Par2">We report a 65&#x02009;years old Cameroonian, previously exposed to raltegravir, and failing on third-line treatment with multi-drug resistance to darunavir/r and dolutegravir. Genotypic resistance testing (GRT) and viral tropism were performed during monitoring time points. The patient initiated ART in August 2007. At the time point of the first (29.04.2010), second (01.12.2017) and third (08.08.2019) GRT, prior ART exposure included 3TC, d4T, NVP and EFV; additionally TDF, DRV/r and RAL; and additionally ABC and DTG respectively. First GRT revealed mutations associated with resistance only to first-generation Non-nucleoside reverse transcriptase inhibitors (NNRTI). Second GRT revealed mutations associated with high-level resistance to all NRTIs, first generation NNRTIs, all ritonavir boosted protease inhibitors (PI/r), and all INSTI, while viral tropism (using geno2pheno) revealed a CCR5-tropic virus with a false positive rate (FPR) of 60.9% suggesting effectiveness of maraviroc (MRV). The third GRT showed high-level resistance to NRTI, NNRTI, all PI and all INSTI, with additional mutations (H221HY for NNRTI and S147G for INSTI), and a CCR5-tropic virus with a slightly reduced FPR (57.0%). Without any locally available active therapeutic option, the patient has been on a maintenance therapy with &#x0201c;DRV/r (600mg x 2/day)+TDF+3TC&#x0201d; and patient/family-centered adherence has been reinforced. Since the first viral load (VL) measurement in 2010, the patient has had 12 VL tests with the VL ranging from 4.97 Log to 6.44 Log copies/mL and the CD4 count never exceeded 200 cells/&#x003bc;L.</p></sec><sec><title>Conclusions</title><p id="Par3">As African countries transition to dolutegravir-based regimens, prior raltegravir-exposure may prompt selection (and potential transmission) of dolutegravir-resistance, supporting case surveillance.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>HIV drug resistance</kwd><kwd>Integrase inhibitors</kwd><kwd>Protease inhibitors</kwd><kwd>Viral tropism</kwd><kwd>Cameroon</kwd></kwd-group><funding-group><award-group><funding-source><institution>Chantal Biya International Reference center for research on HIV/AIDS prevention and management (CIRCB)</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par42">Management of treatment-experienced HIV-patients remains very challenging in resource-limited settings where drug options are limited, poor adherence is frequent, and treatment monitoring (viral load essentially) remains sub-optimal [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. ART program was launched in Cameroon by May 2003, and genotyping drug resistance testing (GRT) is recommended essentially after failing a PI/r-based regimen [<xref ref-type="bibr" rid="CR3">3</xref>]. Following the recent World Health Organisation (WHO) recommendations, most resource-limited settings, including Cameroon, are transitioning to dolutegravir (DTG)-based regimens for first-, second- and/or third-line ART [<xref ref-type="bibr" rid="CR3">3</xref>], with no evidence of DTG-resistance reported in West-Central Africa [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>], and fewer cases in East Africa [<xref ref-type="bibr" rid="CR4">4</xref>]. Of note, few studies reported lower rates of cross-resistance between raltegravir (first-generation integrase strand-transfer inhibitor) and dolutegravir (second-generation integrase strand transfer inhibitor) in Europe [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. Exposure to raltegravir has been previously reported in managing patients with multi-resistant HIV in Africa, but little is known on their effects after transitioning to dolutegarvir-containing regimens [<xref ref-type="bibr" rid="CR9">9</xref>]. Understanding the implications of prior exposure to raltegravir in routine clinical practice would serve as footprint for optimal ART-policies in this transition era, particularly in West and Central Africa and also in all resource-limited settings like Cameroon.</p></sec><sec id="Sec2"><title>Case presentation</title><p id="Par43">This is a 65&#x02009;years old married man, infected with HIV-1 CRF18_cpx. Therapeutic history, VL, CD4 cell counts and genotypic profiles are summarised in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.
<fig id="Fig1"><label>Fig. 1</label><caption><p>CD4-cell and viral load monitoring, ART regimens, and resistance profiles since ART-initiation</p></caption><graphic xlink:href="13756_2020_799_Fig1_HTML" id="MO1"/></fig></p><p id="Par44">The patient was diagnosed with HIV in 2002 and has been on ART for 14 years (since 2006). His initial ART regimen was stavudine (d4T)&#x02009;+&#x02009;lamivudine (3TC)&#x02009;+&#x02009;nevirapine (NVP) from August 2006 to August 2007. NVP was subsequently replaced by efavirenz (EFV) from August 2007 to August 2009. From August 2009, the patient voluntarily stopped treatment and returned to the clinic in 2010 for consultation. In 2010, the patient had a high VL (157,290 RNA copies/ml) and very-low CD4 cell count (87 cells/mm<sup>3</sup>). Prior to ART re-initiation in 2010, genotypic resistance testing (GRT) results, interpreted throughout using Stanford HIVDB (<ext-link ext-link-type="uri" xlink:href="http://www.hivdb.stanford.edu">http://www.hivdb.stanford.edu</ext-link>) and International AIDS Society mutations list, showed the presence of one resistance associated mutation (RAM) to NRTI (V75I), two non-NRTI RAMs (K103I, V108I). With this mutational profile, the patient was recommended PI/r&#x02009;+&#x02009;2NRTI but we have no precision on antiretrovirals used thereafter. From 2011 to 2012, the patient was diagnosed co-infected with pulmonary tuberculosis and treated accordingly, classified as WHO clinical stage 3. After completing anti-tuberculosis treatment in 2012, he was lost to follow-up (duration unclear) and later returned for clinical consultation. Following clinical assessment, he received a regimen consisting of super-boosted ritonavir with darunavir (DRV/r)&#x02009;+&#x02009;raltegravir (RAL)&#x02009;+&#x02009;tenofovir (TDF) +3TC (unclear start date) till November 2017, a period during which adherence was suboptimal (assessed by self-reporting). While completing anti-tuberculosis treatment the patient discontinued HIV-treatment. Following clinical assessment, he was re-initiated with a regimen consisting of ritonavir boosted darunavir (DRV/r)&#x02009;+&#x02009;raltegravir (RAL)&#x02009;+&#x02009;tenofovir (TDF) +3TC (unclear start date) till November 2017; a period during which adherence was suboptimal. A second GRT was performed and the resulting mutational profile suggested DRV/r(600&#x02009;mg &#x000d7;&#x02009;2/day)&#x02009;+&#x02009;DTG(50&#x02009;mg &#x000d7;&#x02009;2/day), possibly associated with ritonavir-boosted atazanavir (ATV/r) for its potential capacity to enhance DTG concentrations (<ext-link ext-link-type="uri" xlink:href="https://www.hiv-druginteractions.org/drug_queries/326049/drug_query_interactions">https://www.hiv-druginteractions.org/drug_queries/326049/drug_query_interactions</ext-link>) as an optimal regimen. However, the patient was prescribed DRV/r(600&#x02009;mg &#x000d7;&#x02009;2/day)&#x02009;+&#x02009;DTG(50&#x02009;mg &#x000d7;&#x02009;1/day)&#x02009;+&#x02009;TDF&#x02009;+&#x02009;3TC from November 2017 to May 2019. In May 2019, the patient was empirically switched to DRV/r(600&#x02009;mg &#x000d7;&#x02009;2/day)&#x02009;+&#x02009;DTG(50&#x02009;mg &#x000d7;&#x02009;1/day)&#x02009;+&#x02009;abacavir (ABC) +3TC. Then, ABC was changed to TDF until August 2019 when the third GRT was performed.</p><p id="Par45">Overall, reported VLs remained around 5 Log<sub>10</sub> copies/mL while CD4-cell counts were consistently &#x0003c;&#x02009;200 cells/mm<sup>3</sup>. Adherence to clinic appointments and drug refill was inconsistent, in spite of adherence supports from health care providers. Apart from anorexia and a 2.8% weight-loss reported over an undefined period, a physical examination, performed in May 2019, was unremarkable [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par46">Following GRTs performed on HIV-1 &#x0201c;<italic>pol&#x0201d;</italic> gene for detecting RAMs and gp120 V3-loop for coreceptor-usage (using the geno2pheno method [<ext-link ext-link-type="uri" xlink:href="https://coreceptor.geno2pheno.org/">https://coreceptor.geno2pheno.org/</ext-link>]) at three different time points [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>], phylogeny consistently revealed the virus to be HIV-1 CRF18_cpx. All sequences generated were submitted to GeneBank (MN52015 &#x02013; MN520219).</p><p id="Par47">The first GRT (April 29, 2010) covered the protease (PR) and reverse transcriptase (RT) regions, with high-level resistance to first-generation NNRTI (K103I, V108I) and no major-RAM to NRTI and PI/r.</p><p id="Par48">The second GRT (December 01, 2017) covered PR and RT regions. Detected RAMs were M41L, K70Q, V75I, Q151M, M184V and T215F for NRTI; K103N and V108I for NNRTI; and L10F, K20I, M36I, M46I, I47V, I54L, L63H, L76V, V82S and L89I for PI/r. These mutations revealed high-level resistance to all NRTIs, first generation NNRTIs (EFV and NVP) and to all PI/r, including DRV/r. Another GRT, covering HIV-1 integrase (IN) region, performed on the sample plasma aliquot, revealed major RAMs, L74I, E138KQ, G140A, Q148R, and E157Q, to integrase strand transfer inhibitors (INSTI) including raltegravir, dolutegravir, bictegravir and elvitegravir. Viral tropism revealed a CCR5-tropic virus, defined by a false positive rate (FPR) of 60.9%, suggesting eligibility for maraviroc (MRV).</p><p id="Par49">The third GRT (August 08, 2019), encompassing PR, RT and IN regions, showed high-level resistance to NRTI, NNRTI, PI and all INSTI. Additional RAMs were H221HY for NNRTI and S147G for INSTI. Viral tropism was also re-performed and demonstrated CCR5-tropic virus with a slightly reduced FPR (57.0%). Pending access to required innovative regimen, a salvage therapy guided by GRT was recommended, consisting of either &#x0201c;DRV/r(600mg x 2/day), saquinavir/r, TDF+3TC&#x0201d;, or &#x0201c;3TC-monotherapy&#x0201d; which maintains M184V and as such limits the viral replicative fitness. None of the recommendations; in November 2019, VL appeared relatively stable (5.54 Log copies/mL) under &#x0201c;DRV/r(600mg x 2/day)+TDF+3TC&#x0201d; and with an active family-centered adherence monitoring. Following intensified/close adherence strategy implemented, the patient is compliant to treatment but the latest plasma viral load remains high, with a slight increment (5.86 Log copies/mL on January 27, 2020), which confirms the need of innovative drugs and close case surveillance, including MRV that is not locally available [<xref ref-type="bibr" rid="CR3">3</xref>].</p></sec><sec id="Sec3"><title>Discussion</title><p id="Par50">To the best of our knowledge, this is the very first clinical case in West and Central Africa of complete four-class multidrug resistance to all antiretrovirals available in resource-limited settings with complete loss of DRV/r and DTG efficacies. Of note, previous report from Cameroon showed a case of successful raltegravir-containing ART for managing a case of multidrug-class-resistance [<xref ref-type="bibr" rid="CR9">9</xref>]. Thus, patients with similar therapeutic management within the country might merit a close monitoring to ensure a successful management in case of ART failure with multi-drug resistance [<xref ref-type="bibr" rid="CR9">9</xref>]. Fewer cases of four-class HIVDR have been recently reported mainly in East and southern African countries, with previous RAL-exposure contributing to ineffectiveness of DTG [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]. Though these previously reported clinical cases were attributed to multi-factorial events, the present clinical case was due to recurrent poor adherence, leading to selection and accumulation of RAMs, followed by exposure to suboptimal drug regimens [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]. Specifically, previous exposure to RAL (a drug with a low-genetic barrier to resistance) in a context of poor adherence contributed to selecting mutations (E138KQ, G140A, Q148R) conferring cross-resistance to DTG [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. In a context with 60&#x02013;80% ADR after ART failure and with documented to RAL has been documented, limiting the use of RAL would preserve DTG for long-term use [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]; and in case of previous exposure to RAL, transition to DTG-based regimens should be guided by GRT in people without VL-suppression [<xref ref-type="bibr" rid="CR3">3</xref>] and if adopted, DTG-dose should be appropriate [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. In addition to non-adherence, consistent low CD4-cell counts (despite a relative increase of CD4 after a nadir of 39cells/mm<sup>3</sup> is attribuable to the use of more potent antiretrovirals), high-VL since ART-initiation, and advanced-age (i.e.&#x02009;&#x0003e;&#x02009;60&#x02009;years) are risk-factors that might have contributed to ART-failure [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]. Additionally, the recombinant virus (HIV-1 CRF18_cpx) may explain to a certain extend the rapid emergence of drug-resistance and the predictive CCR5-tropism [<xref ref-type="bibr" rid="CR17">17</xref>]. The case finding calls essentially for surveillance of acquired (ADR) drug resistance to INSTI in the DTG-era [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. As patient remains clinically stable and sexually active, special patient/family-centered adherence approaches are necessary to limit risk of transmission of four-class drug resistant virus, which may have implications for scale-up of DTG-based ART in resource-limited settings [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. Without any active therapeutic option locally, use of innovative drug combinations consisting preferentially of enfuvirtide, MRV and ibalizumab, is highly recommended (<ext-link ext-link-type="uri" xlink:href="https://www.hiv-druginteractions.org/drug_queries/326049/drug_query_interactions">https://www.hiv-druginteractions.org/drug_queries/326049/drug_query_interactions</ext-link>). Also, as patients on DTG-containing regimens with high baseline VL (&#x0003e;&#x02009;500,000 copies/mL) might experience challenges in viral suppression, close monitoring as well as specific case surveillance should be required even in resource-limited settings like Cameroon [<xref ref-type="bibr" rid="CR18">18</xref>].</p></sec><sec id="Sec4"><title>Conclusion</title><p id="Par51">In the era of transition to DTG-based regimens in resource-limited settings, this clinical case highlights the need for routine ADR population-based surveys to understand the extent of HIVDR to INSTI. Importantly, optimised care/treatment on DTG-containing regimen, alongside adherence support and close VL monitoring, would sustain the efficacy of this therapeutic option. Finally, individual case surveillance after failure to third-line requires genotyping and policies for access to newer drugs in resource-limited settings with similar ART landscapes.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>3TC</term><def><p id="Par4">Emtricitabine</p></def></def-item><def-item><term>ABC</term><def><p id="Par5">Abacavir</p></def></def-item><def-item><term>ADR</term><def><p id="Par6">Acquired drug resistance</p></def></def-item><def-item><term>AIDS</term><def><p id="Par7">Acquired Immunodeficiency Syndrome</p></def></def-item><def-item><term>ART</term><def><p id="Par8">Antiretroviral therapy</p></def></def-item><def-item><term>ATV/r</term><def><p id="Par9">Ritonavir boosted Atazanavir</p></def></def-item><def-item><term>CCR5</term><def><p id="Par10">C-C chemokine receptor type 5</p></def></def-item><def-item><term>CD4</term><def><p id="Par11">Cluster of differentiation four</p></def></def-item><def-item><term>CRF18_cpx</term><def><p id="Par12">Circulating recombinant form complex 18</p></def></def-item><def-item><term>D4T</term><def><p id="Par13">Stavudine</p></def></def-item><def-item><term>DRV/r</term><def><p id="Par14">Ritonavir boosted Darunavir</p></def></def-item><def-item><term>DTG</term><def><p id="Par15">Dolutegravir</p></def></def-item><def-item><term>EFV</term><def><p id="Par16">Efavirenz</p></def></def-item><def-item><term>FPR</term><def><p id="Par17">False positive rate</p></def></def-item><def-item><term>GP 120</term><def><p id="Par18">Envelope glycoprotein 120</p></def></def-item><def-item><term>GRT</term><def><p id="Par19">Genotypic resistance testing</p></def></def-item><def-item><term>HIV</term><def><p id="Par20">Human immunodeficiency virus</p></def></def-item><def-item><term>HIVDR</term><def><p id="Par21">HIV drug resistance</p></def></def-item><def-item><term>IN</term><def><p id="Par22">Integrase</p></def></def-item><def-item><term>INSTI</term><def><p id="Par23">Integrase strand transfer inhibitor</p></def></def-item><def-item><term>LPV/r</term><def><p id="Par24">Ritonavir boosted Lopinavir</p></def></def-item><def-item><term>MRV</term><def><p id="Par25">Maraviroc</p></def></def-item><def-item><term>NNRTI</term><def><p id="Par26">Non-nucleoside reverse-transcriptase inhibitor</p></def></def-item><def-item><term>NRTI</term><def><p id="Par27">Nucleoside reverse-transcriptase inhibitor</p></def></def-item><def-item><term>NVP</term><def><p id="Par28">Nevirapine</p></def></def-item><def-item><term>PDR</term><def><p id="Par29">Pretreatment drug resistance</p></def></def-item><def-item><term>PI/r</term><def><p id="Par30">ritonavir boosted protease inhibitor</p></def></def-item><def-item><term>Pol</term><def><p id="Par31">Polymerase</p></def></def-item><def-item><term>PR</term><def><p id="Par32">Protease</p></def></def-item><def-item><term>RAL</term><def><p id="Par33">Raltegravir</p></def></def-item><def-item><term>RAMs</term><def><p id="Par34">Resistance-associated mutations</p></def></def-item><def-item><term>RNA</term><def><p id="Par35">Ribonucleic acid</p></def></def-item><def-item><term>RT</term><def><p id="Par36">Reverse transcriptase</p></def></def-item><def-item><term>SSA</term><def><p id="Par37">Sub-Saharan Africa</p></def></def-item><def-item><term>TDF</term><def><p id="Par38">Tenofovir disoproxyl fumarate</p></def></def-item><def-item><term>V3</term><def><p id="Par39">Envelope variable region 3</p></def></def-item><def-item><term>VL</term><def><p id="Par40">Viral load</p></def></def-item><def-item><term>WHO</term><def><p id="Par41">World Health Organization</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Carlo-Federico Perno and Alexis Ndjolo contributed equally to this work.</p></fn></fn-group><ack><p>We are appreciative the medical and laboratory staffs involved in the care and monitoring of this patient. We thank Michael Jordan for a thorough review of this manuscript prior to submission.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>JF, ENS, MMS, CFP, EST, GT, VC, DT, BD, GB, LM and AN, initiated the manuscript; All the other co-authors: interpreted the data and revised the manuscript; All the authors: approved the final version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>We also acknowledge financial support from the Chantal Biya International Reference center for research on HIV/AIDS prevention and management (CIRCB), covering the viral load, CD4-cell count and sequencing of HIV-1 protease reverse transcriptase, integrase and V3 loop regions for this patient.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>Data and materials are fully available in the manuscript text and in the figure provided. Sequence data generated are deposited in the public repository of GeneBank, under the following accession numbers from MN52015 to MN520219.</p></notes><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par52">Administrative authorisation was provided by the Directorate General of the Chantal BIYA International Reference for research on HIV/AIDS prevention and management (CIRCB), under the reference number 0191/019/CIRCB/DG/SAA/BRH. Ethical clearance was obtained from the National Ethics Committee for Research on Human Health (reference number 2019/06/34/CE/CNERSH/SP of June 14, 2019). Written informed consent was provided.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par53">Consent has been provided by the patient.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par54">The authors declare they have no personal relationship(s) or financial interests that may have influenced the writing of this report.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grinsztejn</surname><given-names>B</given-names></name><name><surname>Hughes</surname><given-names>MD</given-names></name><name><surname>Ritz</surname><given-names>J</given-names></name><etal/></person-group><article-title>Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study</article-title><source>Lancet HIV</source><year>2019</year><volume>6</volume><issue>9</issue><fpage>e588</fpage><lpage>e600</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(19)30146-8</pub-id><?supplied-pmid 31371262?><pub-id pub-id-type="pmid">31371262</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>AN</given-names></name><name><surname>Stover</surname><given-names>J</given-names></name><name><surname>Cambiano</surname><given-names>V</given-names></name><etal/></person-group><article-title>Impact of HIV drug resistance on HIV/AIDS-associated mortality, new infections, and antiretroviral therapy program costs in sub-Saharan Africa</article-title><source>J Infect Dis</source><year>2017</year><volume>215</volume><issue>9</issue><fpage>1362</fpage><lpage>1365</lpage><pub-id pub-id-type="doi">10.1093/infdis/jix089</pub-id><?supplied-pmid 28329236?><pub-id pub-id-type="pmid">28329236</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Organization WH. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV - Interim guidance: Who; 2018. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/hiv/pub/guidelines/ARV2018update/en/">https://www.who.int/hiv/pub/guidelines/ARV2018update/en/</ext-link>.</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Achieng</surname><given-names>L</given-names></name><name><surname>Riedel</surname><given-names>DJ</given-names></name></person-group><article-title>Dolutegravir resistance and failure in a Kenyan patient</article-title><source>J Infect Dis</source><year>2019</year><volume>219</volume><fpage>165</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiy436</pub-id><pub-id pub-id-type="pmid">30165703</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Fourati S, Charpentier C, Amiel C, et al. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir : a French national study of raltegravir-experienced HIV-1-infected patients. 2015:1&#x02013;6. 10.1093/jac/dku535.</mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and / or Elvitegravir- Resistant HIV-1 : 24-Week Results of the Phase III VIKING-3 Study. J Infect Dis. 2014;210. 10.1093/infdis/jiu051.</mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Eron JJ, Clotet B, Durant J, et al. Safety and Ef fi cacy of Dolutegravir in treatment-experienced subjects with Raltegravir-resistant HIV type 1 infection : 24-week results of the VIKING study. J Infect Dis. 2013;207. 10.1093/infdis/jis750.</mixed-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Requena</surname><given-names>S</given-names></name><name><surname>Trevi&#x000f1;o</surname><given-names>A</given-names></name><name><surname>Cabezas</surname><given-names>T</given-names></name><etal/></person-group><article-title>Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response</article-title><source>J Antimicrob Chemother</source><year>2017</year><volume>72</volume><issue>7</issue><fpage>2083</fpage><lpage>2088</lpage><pub-id pub-id-type="doi">10.1093/jac/dkx090</pub-id><?supplied-pmid 28369593?><pub-id pub-id-type="pmid">28369593</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aghokeng</surname><given-names>AF</given-names></name><name><surname>Kouanfack</surname><given-names>C</given-names></name><name><surname>Peeters</surname><given-names>M</given-names></name><name><surname>Mpoudi-Ngole</surname><given-names>E</given-names></name><name><surname>Delaporte</surname><given-names>E</given-names></name></person-group><article-title>Successful Integrase inhibitor-based highly active antiretroviral therapy for a multidrug-class-resistant HIV type 1 group O-infected patient in Cameroon</article-title><source>AIDS Res Hum Retrovir</source><year>2013</year><volume>29</volume><issue>1</issue><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1089/aid.2012.0196</pub-id><?supplied-pmid 22889147?><pub-id pub-id-type="pmid">22889147</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fokam</surname><given-names>J</given-names></name><name><surname>Salpini</surname><given-names>R</given-names></name><name><surname>Santoro</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon</article-title><source>Arch Virol</source><year>2011</year><volume>156</volume><issue>7</issue><fpage>1235</fpage><lpage>1243</lpage><pub-id pub-id-type="doi">10.1007/s00705-011-0982-3</pub-id><?supplied-pmid 21465085?><pub-id pub-id-type="pmid">21465085</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Fokam J, Bellocchi MC, Armenia D, et al. Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children. Med (United States). 2018;97(13). 10.1097/MD.0000000000010176.</mixed-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chimbetete</surname><given-names>C</given-names></name><name><surname>Katzenstein</surname><given-names>D</given-names></name><name><surname>Shamu</surname><given-names>T</given-names></name><etal/></person-group><article-title>HIV-1 drug resistance and third-line therapy outcomes in patients failing second-line therapy in Zimbabwe</article-title><source>Open Forum Infect Dis</source><year>2018</year><volume>5</volume><issue>2</issue><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/ofid/ofy005</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossouw</surname><given-names>TM</given-names></name><name><surname>Hitchcock</surname><given-names>S</given-names></name><name><surname>Botes</surname><given-names>M</given-names></name></person-group><article-title>The end of the line? A case of drug resistance to third-line antiretroviral therapy</article-title><source>South Afr J HIV Med</source><year>2016</year><volume>17</volume><issue>1</issue><fpage>3</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.4102/sajhivmed.v17i1.454</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seatla</surname><given-names>KK</given-names></name><name><surname>Avalos</surname><given-names>A</given-names></name><name><surname>Moyo</surname><given-names>S</given-names></name><etal/></person-group><article-title>Four-class drug-resistant HIV-1 subtype C in a treatment experienced individual on dolutegravirbased antiretroviral therapy in Botswana</article-title><source>Aids.</source><year>2018</year><volume>32</volume><issue>13</issue><fpage>1899</fpage><lpage>1902</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000001920</pub-id><?supplied-pmid 29894383?><pub-id pub-id-type="pmid">29894383</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pena</surname><given-names>MJ</given-names></name><name><surname>Chueca</surname><given-names>N</given-names></name><name><surname>D&#x02019;Avolio</surname><given-names>A</given-names></name><name><surname>Zarzalejos</surname><given-names>JM</given-names></name><name><surname>Garcia</surname><given-names>F</given-names></name></person-group><article-title>Virological Failure in HIV to Triple Therapy With Dolutegravir-Based Firstline Treatment: Rare but Possible</article-title><source>Open forum Infect Dis</source><year>2019</year><volume>6</volume><issue>1</issue><fpage>ofy332</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofy332</pub-id><?supplied-pmid 30631792?><pub-id pub-id-type="pmid">30631792</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hocqueloux</surname><given-names>L</given-names></name><name><surname>Raffi</surname><given-names>F</given-names></name><name><surname>Prazuck</surname><given-names>T</given-names></name><etal/></person-group><article-title>Dolutegravir Monotherapy versus Dolutegravir/Abacavir/lamivudine for Virologically suppressed people living with chronic human immunodeficiency virus infection: the randomized noninferiority MONotherapy of TiviCAY trial</article-title><source>Clin Infect Dis</source><year>2019</year><volume>69</volume><issue>9</issue><fpage>1498</fpage><lpage>1505</lpage><pub-id pub-id-type="doi">10.1093/cid/ciy1132</pub-id><?supplied-pmid 30601976?><pub-id pub-id-type="pmid">30601976</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Giorgi</surname><given-names>EE</given-names></name><name><surname>Ganusov</surname><given-names>VV</given-names></name><etal/></person-group><article-title>Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection</article-title><source>Nat Commun</source><year>2018</year><volume>9</volume><issue>1</issue><fpage>1928</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-04217-5</pub-id><?supplied-pmid 29765018?><pub-id pub-id-type="pmid">29765018</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charles</surname><given-names>K</given-names></name><name><surname>Mireille</surname><given-names>M-E</given-names></name><name><surname>Pierrette</surname><given-names>OB</given-names></name><etal/></person-group><article-title>Dolutegravir-based or low-dose Efavirenz&#x02013;based regimen for the treatment of HIV-1</article-title><source>N Engl J Med</source><year>2019</year><volume>381</volume><issue>9</issue><fpage>816</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.1056/nejmoa1904340</pub-id><pub-id pub-id-type="pmid">31339676</pub-id></element-citation></ref></ref-list></back></article>